REPLIGEN CORP Restructuring Charges
REPLIGEN CORP (RGEN) reported Restructuring Charges of $2.72 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2026-07-29
- REPLIGEN CORP restructuring charges for the quarter ending 2026-06-30 was $2.72M, a 25.72% increase year-over-year.
- REPLIGEN CORP restructuring charges for the quarter ending 2026-03-31 was $1.50M, a 24.18% decline year-over-year.
- REPLIGEN CORP restructuring charges for the quarter ending 2025-06-30 was $2.16M.
- REPLIGEN CORP restructuring charges for the quarter ending 2025-03-31 was $1.97M.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month |
|---|---|---|---|
| 2026-06-30 | $2.72M 10-Q · filed 2026-07-29 | $4.21M 10-Q · filed 2026-07-29 | |
| 2026-03-31 | $1.50M 10-Q · filed 2026-05-06 | ||
| 2025-06-30 | $2.16M 10-Q · filed 2026-07-29 | $4.13M 10-Q · filed 2026-07-29 | |
| 2025-03-31 | $1.97M 10-Q · filed 2026-05-06 | ||
| 2023-09-30 | $26.00M 10-Q/A · filed 2024-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |